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ABSTRACT
Background: Long acting injectable antipsychotics (LAI-APs) are considered a major advance in psy-
chiatric treatment concerning treatment adherence and outcomes. Yet, both, doctors and patients
remain sceptical.
Aim: To explain the rationale for using LAI-APs, review their effectiveness and explore barriers to use.
Method: Clinical overview of LAI-APs from the patient and doctor’s perspective.
Results: LAI-APs were developed to increase adherence to treatment, thereby improving treatment
outcomes. LAI-APs may reduce the risk of relapse and hospitalisation. Yet, the evidence from the few
meta-analyses available remains weak. Both patients and doctors may associate LAI-APs with stigma
and coercion. Current means of improving adherence include more focus on the therapeutic relation-
ship, better information, adverse effects minimisation and half-life extension of LAI-APs. Future means
of improving adherence include novel administration techniques that abolish the need for injection.






The rationale for long acting injectable (LAI)
antipsychotics
The introduction of antipsychotics (AP) in the early 1950s
heralded a start of a new era for the treatment of schizo-
phrenia. For the first time, drugs became available that could
effectively treat the positive symptoms of schizophrenia,
including delusions, hallucinations and thought disorder.
These first-generation antipsychotics (FGAs) significantly
reduced or even eliminated harsh and ill-fated treatment
attempts such as convulsive therapies or physical restraints
[1]. Yet, despite the initial therapeutic success, it soon
emerged that many patients only poorly adhered to these
novel oral formulations [2]. This prompted the development
of LAI-APs in the early 1960, first as fluphenazine and halo-
peridol deaconate. With the advent of second generation
antipsychotics [2], LAI-FGAs use declined. But despite
improved tolerability, adherence to oral SGAs did not prove
any better than to oral FGAs. LAI-SGAs were developed once
again to improve adherence rates [2]. Thus, the goal of LAI
treatment has remained the same, to improve adherence as
a means to reduce the risk of symptom exacerbation, relapse
and hospitalisation [3,4].
Non-adherence to oral APs
Non-adherence to oral APs (OPAs) remains high. Estimates
vary between 40–90% [3]. Non-adherence may explain treat-
ment resistance in a significant number of patients. In a
study of 99 patients, thought to be treatment resistant on
OAPs, 35% had sub-therapeutic or undetectable plasma lev-
els Patients with sub-therapeutic or undetectable plasma lev-
els were about three times more likely to be admitted to
hospital [4].
Adherence to OAPs can be notoriously difficult to
establish. Both patients and clinicians may over-report or
overestimate adherence. A study conducted in 52 outpa-
tients with schizophrenia or schizoaffective disorder com-
pared four measures of adherence. These included patient
self-reports, clinician estimates, pill count and a medica-
tion event monitoring system (MEMS). Via a microproces-
sor in the cap, MEMS recorded when and how often a
medication bottle was opened. Adherence estimated var-
ied with measure; 95% for patient self-reports, 76% for
clinician estimates, 74% for pill count, and 48% for
MEMs [5].
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Effectiveness of SGR LAIs
Several studies have shown that LAI-APs may reduce the risk
of relapse and hospitalisation. There is also some preliminary
evidence that LAIs may reduce comorbid violent behaviour
in patients with schizophrenia [6,7].
LAI risperidone
A randomised controlled trial (RCT) compared oral and LAI
risperidone in 83 patients with recent onset of schizophrenia.
The risk of exacerbation and/or relapse was significantly
lower in patients treated with LAI-risperidone (7%) than with
oral risperidone (50%) within one year. Mean time to relapse
was significantly longer [8]. Another retrospective study
showed that LAI- risperidone significantly reduced the admis-
sions and length of stay [9].
LAI-paliperidone
In a prospective study of 210 patients being consecutively
prescribed paliperidone palmeate, 65% of the patients were
still receiving the LAI formulation after one year [10]. In a fur-
ther prospective follow-up of 225 patients treated with pali-
peridone palmitate, 42% were still retained on the
medication after two years. In this study, there was also a
significant reduction of mean bed days. They decreased from
79.6 in the two years before to 46.2 in the two years after
start of paliperidone palmitate [11]. Bressington et al. 2015
also found a significant reduction of bed days after paliperi-
done palmitate initiation [12]. In a multicentre randomised
controlled trial of paliperidone palmitate against oral APs,
risk of relapse within 24 months was reduced by 29% with
the LAI. Time to relapse was also significantly longer in the
LAI than in the oral AP group [13].
LAI aripiprazole
In a prospective study of 160 patients consecutively treated
with aripiprazole LAI, 51% still received the agent after one
year. Mean number of admissions fell significantly from 0.71/
patient/year in the three years before to 0.45/patient in the
year after aripiprazole LAI initiation. Equally significantly
decreased mean number of bed days from 30.4/patient in
the three years before to 22.8/patient in the year after aripi-
prazole LAI initiation. Median bed days fell from 21.7 to zero
in the same time frame [14].
Meta-analyses
There are few meta-analyses. These show conflicting results
and are less optimistic. The most recent meta-analyses stem
from 2016 and 2017 [15,16]. Kishi et al. compared LAI- SGAs
with OAPs in patients with recent-onset psychotic disorder.
This analysis, including five RCTs conducted between 2009
and 2015, concluded that LAI-APs were not superior prevent-
ing the relapse but outperformed OAPs in terms of adher-
ence and discontinuation due to ineffectiveness. LAI-APs had
a higher incidence of at least one adverse effect and tremor
[15]. Ostuzzi et al. compared LAI-FGAs and SGAs with OAPs
from 18 RCTs conducted between 1964 and 2015. This study
concluded that there was no robust evidence for better tol-
erability and efficacy of LAI-APs [16]. However, patients with
better adherence may be more likely to participate in trials.
Selection bias may then reduce any potential difference
between OAPs and LAI-APs.
Obstacles to LAIs use
Both patients and clinicians may reject LAI-APs. Reasons
partly overlap. In a survey of 317 psychiatrists, 69% regarded
LAI-APs less acceptable to the patients, 48% as stigmatising,
40% as old fashioned and 38% more prone to adverse
effects [17]. Patients may indeed associate LAIs with stigma
and coercion [18]. Fear of needles and injection pain may
also shape negative attitudes towards LAI-APs [19].
In a study of 222 outpatients with schizophrenia or schiz-
oaffective disorder, 43% currently treated with LAI-APs pre-
ferred this route of administration [20]. Conversely, only 6%
currently treated with tablets would have preferred LAI-APs.
Prior negative experience with AP and particularly LAI-AP
treatment affected attitudes towards LAI-APs. Type of formu-
lation may not drive attitudes towards AP. Need for treat-
ment and symptom attribution to the underlying mental
illness predicted appositive attitude towards antipsychotics.
Extrapyramidal side effects shaped a negative attitude [20].
Overcoming barriers to LAI use
Information about LAI-APs and a good therapeutic relation-
ship may promote LAI-APs use. In this context, it may be par-
ticularly important to rectify possible misconceptions about
LAI-AP use. Patients may not know that LAI options exist, or
they may associate injections with higher costs and even
with addiction [18]. Doctors, on the other hand, may believe
that LAI-APs cannot be used in first episode psychosis [21].
Minimising adverse effects
Choosing SGA LAI-APs over FGA LAI-APs and refraining from
excessive doses may improve adherence. The use of FGA
LAI-APs is particularly associated with tardive dyskinesia. Up
to 11% of the patients may be affected [22]. Using FGAs LAI-
APs in escalating doses is therapeutically counter-productive.
Optimising haloperidol deaconate dosing illustrates this. At a
dose of haloperidol deaconate 100mg/4weeks, correspond-
ing to a daily total dose of 5mg of oral haloperidol, about
90% of all the patients remain well. At a dose of haloperidol
deaconate 300mg/4weeks, corresponding to a daily total
dose of 30mg of oral haloperidol, about 92% of all patients
remain well. There is only marginal improvement in relapse
prevention. But there is a much higher risk dose-dependent
of extrapyramidal side effects [23]. Changing the formulation
of LAI-APs is a way of preventing adverse effects
associated with the injection itself. Oil-based formulations
used in LAI-FGAs are more likely to cause scar tissue, when
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used long-term. All later LAI-SGAs may minimise injection-
related adverse effects by using aqueous solutions instead
(Table 1).
Extending half-life
Extending the half-life of LAI-APs may be another effective
way to improve adherence. Besides this, a longer half-life
may extend the time to relapse once a LAIs is discontinued
[24]. Experience from the Maudsley Hospital in London
shows that only few patients discontinue LAI paliperidone
given at a three-monthly interval. Advantages must be offset
against the disadvantage. On one hand, longer half-life LAI-
APs mean fewer injections overall, more autonomy, fewer
visits to mental health facilities and lower risk of admission.
On the other hand, longer half-life LAIs may be perceived as
high dose with an increased risk of adverse events. Further
potential draw-backs include loss of regular contact with the
community mental health team. Injection pain due to admin-
istration of a higher volume may be a further disadvantage.
New ways of delivering LAI-APs
The concept of using LAI-APs to improve adherence and
reduce the risk of relapse remains appealing but meta-ana-
lytic evidence is inconclusive. Patients and doctors remain
sceptical as well. LAI-FGAs were all oil-based. Developing for-
mulations that are long-acting but not injectable (LANI-APs)
may be another way to improve outcomes. Such novel for-
mulations could do away with the unpleasantness of injec-
tion. If delivery to the brain could be optimised, they might
also reduce the amount of drug to be administered. Finally,
some formulations could make administration reversible, a
significant advantage if faced with serious adverse event
such as neuroleptic malignant syndrome. Here, we present
and discuss some of the novel techniques of drug delivery
that may become available in the future.
Drug administration via nasal cavity
Drug administration via nasal cavity provides rapid absorp-
tion into systemic circulation and avoidance of enzymatic
degradation and first pass effect. Compared to oral delivery,
intranasal delivery results in rapid onset of activity and
enhanced bioavailability. Drugs can be targeted to the brain
directly through olfactory and trigeminal nerve ending
regions bypassing the blood-brain-barrier (direct pathway).
This is a way to increase drug delivery to the brain and
hence efficacy. At the same time, drug delivery to the per-
iphery is decreased. This can potentially alleviate the risk of
systemic adverse effects such as cardiovascular or metabolic
problems [25]. Reduced systemic concentrations may also
benefit patients with severe renal or hepatic impairment.
There is no antipsychotic substance approved or under
examination in clinical trials based on intranasal drug deliv-
ery for brain targeting. However, there has been a great
interest among the researchers in exploiting the benefits of
intranasal brain targeting. This has resulted in the develop-
ment of novel drug delivery approaches like solid lipid nano-
particles, polymeric nanoparticles or nanoemulsions [26]. For
example, intranasal administration olanzapine loaded- PLGA
microparticles to rats showed higher brain concentration
(>10 times) of the drug as compared to the IV solution [27].
Specialised devices such as OptiNose and ViaNase electronic
atomizer have also been developed to administer different
drugs to middle and upper posterior regions of the nose for
enhanced brain targeting. These studies showed a great
potential for intranasal drug delivery of antipsychotics. But
translating this research into successful clinical products
depends on the local and systemic toxicity and safety of the
drug loaded nanoparticulate systems. Long-term effects of
higher concentrations of the drug in brain should also
be studied.
Drug loaded implants
While LAI-APs may enhance the compliance and decrease
the morbidity and mortality as compared to OAPs, depot
injections are irreversible and thus lack flexibility clinical
management. Besides, some LAI-APs can cause prolonged
pain and scar tissue at the injection site. This coupled with a
perceived stigma of injections can result in treatment discon-
tinuation. Drug loaded implants for subcutaneous administra-
tion offer an alternative and novel drug delivery option for
very long-term delivery of APs. Contrary to injectable drugs,
implants could be removed after disposition. This reversibility
of administration could be a significant advantage when
managing risks of severe adverse drug reactions such as
neuroleptic malignant syndrome. No product based on this
technology is yet on the market, but clinical trials are under
way. In a recent study on pharmacokinetics and safety of ris-
peridone subcutaneous implants in patients with schizophre-
nia, therapeutic drug levels were quickly achieved and
maintained near constant rates over six months [28]. This
demonstrating the viability and potential of this
new technology.
Table 1. Summary of form of active drugs and formulation details of different








Fluphenazine Decanoate prodrug Solution in sesame oil
Haloperidol Decanoate prodrug Solution in sesame oil
Pipothiazine Palmitate prodrug Solution in sesame oil
Zuclopenthixol Decanoate prodrug Solution in sesame oil
Perphenazine Decanoate prodrug Solution in sesame oil
LAI-SGAs
Risperidone Free base Polymeric microspheres
(aqueous formulation)
Olanzapine Pamoate salt Freeze dried powder for
aqueous suspension
Paliperidone Palmitate prodrug Nanocrystals in aqueous suspension
Aripiprazole Monohydrate Powder for aqueous suspension
Aripiprazole Lauroxil ester prodrug Ready-to-use aqueous suspension
LAI-Aps: long-acting injectable antipsychotics; LAI-FGAs: long-acting injectable
first-generation antipsychotics; LAI-SGAs: long-acting injectable second-gener-
ation antipsychotics.
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Conclusions
LAI-APs are an important clinical tool for improving adher-
ence. Yet many patients and doctors perceive LAI-APs as
coercive, old-fashioned and stigmatising. Means of overcom-
ing barriers to LAI-AP use include a good therapeutic rela-
tionship, use of SGA-LAIs over FGA-LAIs and avoidance of
excessive doses to minimise adverse effects. Novel intra-nasal
and implant formulations may remove disadvantages of
injectable such as irreversibility over several weeks, injection
pain and scar tissue formation. Such novel formulations
could also help to change the reputation of APs from old
fashioned to high tech.
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